AstraZeneca’s Iressa, Now Resurrected, Faces Daunting U.S. EGFR Market

AstraZeneca sees an edge on safety for Iressa, which was traditionally perceived as having attractive tolerability relative to other EGFR inhibitors, but firm still has a tough road competing against the omnipresent Tarceva.